<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100791">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01864759</url>
  </required_header>
  <id_info>
    <org_study_id>ICOVIR5-2</org_study_id>
    <secondary_id>2008-005694-35</secondary_id>
    <nct_id>NCT01864759</nct_id>
  </id_info>
  <brief_title>Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma</brief_title>
  <official_title>Phase I Clinical Trial of Endovenous Administration of Conditionally Replicative Adenovirus ICOVIR-5 in Patients With Locally Advanced or Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Català d'Oncologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Català d'Oncologia</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will evaluate the safety of a single endovenous infusion of ICOVIR5 in
      adults with locally advanced and metastatic melanoma. ICOVIR5 consists in a conditionally
      replicative or oncolytic adenovirus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The highest dose where less than two out of three or six patients suffered dose limiting toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recommended dose</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumour activity</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Viral pharmacokinetics</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Viremia at 0 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours and 24 hours after endovenous injection.</description>
  </other_outcome>
  <other_outcome>
    <measure>Viral pharmacodynamics</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Virus presence in tumors at day 5 post-administration.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Locally Advanced or Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>ICOVIR5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ICOVIR-5 oncolytic adenovirus, single administration, endovenous, dose escalation from 1E11 vp to 1E13 vp.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ICOVIR-5</intervention_name>
    <arm_group_label>ICOVIR5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Malignant melanoma advanced or metastatic.

          -  Other than 18 years

          -  Karnofsky index &gt; 60 %

          -  Life expectancy &gt; 3 months

          -  ALT/AST &lt;=2.5 times the upper normal limit

          -  Creatinine clearance &gt;= 50 ml/min.

          -  Bilirubin &lt;25 umol/l

          -  Alkaline phosphatase &lt;= 2.5 time upper normal limit

          -  Normal bone marrow function: Neutrophils &gt;=1.5 E9/L, platelets &gt;= 1E11/L, hemoglobin
             &gt;= 100 g/l, Normal prothrombin time and thromboplastin time,

          -  HIV negative

          -  Measurable disease

          -  Signed informed consent.

        Exclusion Criteria:

          -  Geographical, social or psychological conditions that may impair the protocol
             compliance.

          -  Active infections or other severe medical status.

          -  History of liver disease.

          -  Other or concomitant treatments for melanoma or investigational product.

          -  Previous participation in studies with adenovirus.

          -  Virus diseases diagnosed two weeks before inclusion.

          -  Immunosuppressive concomitant treatments

          -  Concomitant malignant haematological disease.

          -  Patients having family members with immunodeficient status or disease

          -  Patients with Li Fraumeni syndrome or germinal retinoblastoma gene defects.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramon Salazar, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Catala D'Oncologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramon Alemany, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Català d'Oncologia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ramon Salazar, MD PhD</last_name>
    <phone>34.93.260.77.44</phone>
    <email>ramonsalazar@iconcologia.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marta Gil, MD</last_name>
    <phone>34.93.260.77.44</phone>
    <email>mgilmartin@iconcologia.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Català d'Oncologia - L'Hospitalet</name>
      <address>
        <city>L'Hospitalet del Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ramón Salazar, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Gil, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Ochoa de Olza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Cascallo M, Alonso MM, Rojas JJ, Perez-Gimenez A, Fueyo J, Alemany R. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol Ther. 2007 Sep;15(9):1607-15. Epub 2007 Jun 19.</citation>
    <PMID>17579575</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>May 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>oncolytic</keyword>
  <keyword>adenovirus</keyword>
  <keyword>virotherapy</keyword>
  <keyword>locally advanced</keyword>
  <keyword>metastatic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenoviridae Infections</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
